Health officials have given a life-extending drug the green light for widespread NHS, giving hope to thousands of men facing a "death sentence" from prostate cancer.
The National Institute for Health and Care Excellence (Nice) said the drug enzalutamide, also known as xtandi, should be considered for use in the treatment of men with hormone relapsed prostate cancer that has spread to other parts of the body.
Nice said in its draft guidance that it was pleased to recommend the drug, which is manufactured by Astellas Pharma, for patients who have few other treatment options left.
More top news
A doggy intelligence test may hold the key to a better understanding of human health problems like dementia, scientists say.
The Duchess says that children should be "supported through difficult times in their lives" at the start of Children's Mental Health Week.
The Met Police could soon be using birds of prey to help keep the skies above London clear of crime.